Search

Abstract Objective This study aims to describe the diagnostic performance of alpha-fetoprotein (AFP), alpha-fetoprotein L3 isoform (AFP-L3), protein induced by vitamin K absence II (PIVKA-II), and combined biomarkers for non-B non-C hepatocellular carcinoma (NBNC-HCC). Results A total of 681 newly-diagnosed primary liver disease subjects (385 non-HCC, 296 HCC) who tested negativity for the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV) enrolled in this study. At the cut-off point of 3.8 ng/mL, AFP helps to discriminate HCC from non-HCC with an area under the curve (AUC) value of 0.817 (95% confidence interval [CI]: 0.785–0.849). These values of AFP-L3 (cut-off 0.9%) and PIVKA-II (cut-off 57.7 mAU/mL) were 0.758 (95%CI: 0.725–0.791) and 0.866 (95%CI: 0.836–0.896), respectively. The Bayesian Model Averaging (BMA) statistic identified the optimal model, including patients’ age, aspartate aminotransferase, AFP, and PIVKA-II combination, which helps to classify HCC with better performance (AUC = 0.896, 95%CI: 0.872–0.920, P

Abstract Background The plasma‐based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results. Aim This meta‐analysis aims to clarify the role of the EGFR‐plasma test in prognosis for non‐small cell lung cancer (NSCLC) who have mutant tumors and receive EGFR tyrosine kinase inhibitors (TKIs). Methods and Results The PubMed/MEDLINE, Web of Science, Cochrane Library, and Google Scholar databases were searched for relevant studies by April 10, 2021. The hazard ratio (HR) from reports was extracted and used to assess the correlation of EGFR‐plasma status with progression‐free survival (PFS) and overall survival (OS). A total of 35 eligible studies with 4106 patients were enrolled in the final analysis. Patients with concurrent EGFR mutations in pretreatment plasma have shorter PFS (HR = 2.00, 95% confidence interval [CI]: 1.73–2.31, p

Abstract Objective This study aimed to identify the influential factors for the sensitivity of epidermal growth factor receptor (EGFR) plasma test in non-small cell lung cancer (NSCLC). The mutations were detected in tumor tissue and matched plasma samples from 125 newly diagnosed adenocarcinoma, clinical-stage IIIB-IV patients, and compared the diagnostic values of EGFR plasma test between groups of clinical characteristics. The influential factors for the sensitivity were identified and assessed by logistic regression. Results EGFR mutations were detected in 65 (52.0%) tumor tissue and 50 (40.0%) matched plasma samples (P = 0.028). Compared to the tissue method, the concordance rate, sensitivity, and specificity of the EGFR plasma test were 86.4%, 75.4%, and 98.3%, respectively. Notably, we found that sensitivity of the test is higher in non-smokers (84.1%) compared to smokers (57.1%, P = 0.018), and in treatment naïve subjects (85.7%) compared to whom undergone chemo-radiotherapy with/without surgery before testing (56.5%, P = 0.009). Furthermore, the highest sensitivity was attained in patients without these two factors (90.3%), whilst the lowest value was noted in those with both factors (40.0%, P = 0.004). The multivariable analysis confirmed that smoking habit and treatment history have independently negative impacts on sensitivity (OR = 0.24, P = 0.019, and OR = 0.36, P = 0.047, respectively).

Abstract Objective The same immuno-phenotype between HLA-DR-negative acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) causes APL rapid screening to become difficult. This study aimed to identify the associated antigens for APL and the best model in clinical uses. Results A total of 36 APL (PML–RARA+) and 29 HLA-DR-negative non-APL patients enrolled in this study. When a cut-off point of 20% events was applied to define positive or negative status, APL and non-APL patients share a similar immuno-phenotype of CD117, CD34, CD11b, CD13, CD33, and MPO (P > 0.05). However, expression intensity of CD117 (P = 0.002), CD13 (P

Abstract Background This study aims to clarify the prognostic role of epidermal growth factor receptor (EGFR) mutations in plasma of non-small cell lung cancer (NSCLC) for resistance to tyrosine kinase inhibitor (TKI), in correlation with clinical characteristics. A total of 94 Adenocarcinoma, clinical stage IV NSCLC patients with either E19del or L858R mutation were admitted to the prospective study from Jan-2016 to Jul-2018. EGFR mutations in plasma were detected by scorpions ARMS method. The Kaplan–Meier and Cox regression methods were used to estimate and test the difference of progression-free survival (PFS) and overall survival (OS) between groups. The prognostic power of each factor was appraised by the Bayesian Model Averaging (BMA) method. Results Among 94 patients, 28 cases still are good responses according to the RECIST criteria and negative for EGFR mutations in plasma. Of 66 resistant patients, EGFR mutations were positive in plasma of 57 cases (86.4%) which was higher than the value of pre-treatment (48.5%). Of which, 17 patients (25.8%) have the occurrence of EGFR mutations in plasma earlier than progression 2.1 (0.6–7.9) months. The secondary T790M mutation was found in the plasma of 32 cases (48.5%). Median PFS and OS for the study subjects were 12.9 (11.0–14.2) and 29.5 (25.2–41.3) months, respectively. The post-treatment EGFR plasma test with brain and new metastasis were detected as independent prognostic factors for worse PFS (P = 0.008, 0.016 and 0.028, respectively). While EGFR plasma (P = 0.044) with bone metastasis at baseline (P = 0.012), new metastasis (P = 0.003), and high cfDNA concentration (P = 0.004) serve as the worse survival factors, surgery treatment helps to prolong OS in NSCLC treated with EGFR TKI (P = 0.012). BMA analysis identified EGFR plasma test as the strongest prognostic factor for both PFS and OS (possibility of 100% and 99.7%, respectively). Conclusions EGFR plasma test is the powerfully prognostic factor for early resistance with EGFR TKI and worse survival in NSCLC regardless of clinical characteristics.

Tomato is one of the popular vegetables in the world. However, drought has become more serious in recent years. Drought strongly reduced the development and yield of tomato. Thus, the effect of drought stress condition (½ Murashige and Skoog’s medium supplemented with 35 g.L-1 mannitol) and thermal pre-treatment (45 (C for 120 min) on in vitro shoot development of Solanum lycopersicum L. were studied to improve the drought-tolerant of tomato. Morphological, physiological and biochemical changes during the development of in vitro shoot in the drought stress condition were analyzed. Then, leaves of the shoot that pre-treated at 45 (C for 120 min and developed on the drought stress condition were cultured on ½ MS medium supplemented with 20 g.L-1 sucrose, 0.1 mg.L-1 Indole acetic acid, 2 mg.L-1 zeatin and 35 g.L-1 mannitol to regenerate the drought-tolerant shoots. In the drought stress condition (½ MS medium with 35 g.L-1 mannitol), the height of shoot, the number of leaves, and the total leaf area were decreased by approximately 50 % compared to control (½ MS medium without mannitol). Besides, the leaf midrib thickness and the vascular bundle width of the leaf in drought stress were smaller than those of the control. The leaf midrib thickness and the leaf vascular bundle width in drought stress condition were 953.30 (m and 320.21 (m, compared to 1243.80 (m and 410.15 (m in that of control. Chlorophyll fluorescence occurs in some parenchyma cells near the midrib vascular bundle of treated leaves instead of all parenchyma cells in control leaves. Under the drought stress condition, chlorophyll content, photosynthetic intensity and cytokinin activity of leaf were strongly decreased but respiration intensity, the content of carotenoid and proline, especially the activity auxin and abscisic acid were increased. Thermal pre-treatment stimulated shoot regeneration (2.53 shoots/leaf explant) while there was no shoot regenerated from the leaf of the control plant. The shoots regenerated by this method grew well in the drought stress condition.

Nghiên cứu này được thực hiện ở Khoa Sư phạm, Trường Đại học Cần Thơvà có hai mục đích. Một là xác định số lượng câu hỏi trung bình được đặt ra trong một tiết học. Hai là khảo sát những loại câu hỏi được đặt ra. Việc phân loại câu hỏi trong khảo sát này lấy thang phân loại câu hỏi Bloom (1956) làm cơ sở. Theo đó có 6 mức độ tư duy là “Biết”, “Hiểu”, “Áp dụng”, “Phân tích”, “Tổng hợp”, và “Đánh giá”. Nghiên cứu này dựa trên 60 tiết quan sát lớp học để ghi lại những câu hỏi mà các giảng viên đặt ra. Những giảng viên này được lựa chọn ngẫu nhiên và đến từ hầu như tất cả các bộmôn của Khoa Sư phạm. Đểđối chiếu với kết quả quan sát lớp học trước đó, nghiên cứu còn bao gồm 20 cuộc phỏng vấn trực tiếp từng người với 20 sinh viên ngẫu nhiên của khoa Sư phạm, để từđó rút ra những kết luận đúng đắn. Những kết quả nghiên cứu cho thấy rằng số lượng câu hỏi trung bình trong một tiết học là 10.33 và hai loại câu hỏi “Biết” và “Hiểu” được đặt ra nhiều hơn so với những loại câu hỏi khác trong lớp học. ...

Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, immune evasion, and tumor metastasis has prompted various studies to investigate their clinical significance as a biomarker of predictive and prognostic value across different cancer types. Yet, the methodologies to investigate the polarization phenomena in solid tumor tissue vary. Nonetheless, quantifying the ratio of M1 to M2 TAMs has emerged to be a prevailing parameter to evaluate this polarization phenomena for clinical application. This mini-review focuses on recent studies exploring clinical significance of M1/M2 TAM ratio in human cancer tissue and critically evaluates the technicalities and challenges in quantifying this parameter for routine clinical practice. Immunohistochemistry appears to be the preferred methodology for M1/M2 TAM evaluation as it is readily available in clinical laboratories, albeit with certain limitations. Recommendations are made to standardize the quantification of TAMs for better transition into clinical practice and for better comparison among studies in various populations of patients and cancer types., (Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng.)